Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Unlocking the growth for pharma companies in India

Ahead of the upcoming CPhI India conference in late November, IMS Health provides an overview of this high growth market and how pharma can unlock its potential. When the vibrancy of a new market is as compelling as the pharma market in India, the scrabble to get a foothold is intense. With an average growth rate forecast of…

Articles

Three men, 140 miles and a bunch of health apps

Some of our authors go to great lengths to help pharma advance – 140 miles in this case as team Refreshed Wellbeing test several health apps during a charity cycle ride. Back in September, a few of the folks at Refreshed Wellbeing slapped on the muscle rub and strapped on their helmets for a cycle ride from our offices in Reigate to…

Articles

Tunnah’s musings: bad pharma, good pharma or better patients...

This month, Paul Tunnah muses on what the pharma industry has in common with Lance Armstrong – and it’s not all about the bike or the drugs. I feel rather sorry for Lance Armstrong. It may not be popular sentiment to say that right now, but I suspect I’m not the only one…

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital